Ipsen (BATS-CHIXE:IPNP) - Stock Price, News & Analysis

IPNP Stock Overview

Operates as a biopharmaceutical company worldwide.

IPNP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 61.6% below our estimate of its fair value

Earnings are forecast to grow 6.63% per year

Earnings grew by 63.4% over the past year

Risk Analysis

Shares are highly illiquid

Ipsen S.A. Competitors

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

GSK

LSE:GSK

UK£67.5b

AstraZeneca

LSE:AZN

UK£204.5b

Animalcare Group

AIM:ANCR

UK£161.8m

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price	€109.75
52 Week High	€127.75
52 Week Low	€102.10
Beta	0.60
11 Month Change	6.76%
3 Month Change	-9.00%
1 Year Change	-5.92%
33 Year Change	33.27%
5 Year Change	19.16%
Change since IPO	437.33%

Recent updates

Shareholder Returns

	IPNP	GB Pharmaceuticals	GB Market
7D	7.5%	0.7%	-0.7%
1Y	-5.9%	21.2%	9.7%

Return vs Industry: IPNP underperformed the UK Pharmaceuticals industry which returned 21.2% over the past year.

Return vs Market: IPNP underperformed the UK Market which returned 9.7% over the past year.

Price Volatility

Is IPNP's price volatile compared to industry and market?
IPNP volatility
IPNP Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: IPNP has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IPNP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1929	5,325	David Loew	www.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPNP fundamental statistics
Market cap	€9.04b
Earnings (TTM)	€663.90m
Revenue (TTM)	€3.44b

13.6x

P/E Ratio

2.6x

P/S Ratio

Is IPNP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IPNP income statement (TTM)
Revenue	€3.44b
Cost of Revenue	€618.00m
Gross Profit	€2.82b
Other Expenses	€2.15b
Earnings	€663.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	8.04
Gross Margin	82.01%
Net Profit Margin	19.33%
Debt/Equity Ratio	9.6%

How did IPNP perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

15%

Payout Ratio

IPNP Stock Overview

Rewards

Risk Analysis

Ipsen S.A. Competitors

LSE:HIK

UK£4.3b

LSE:GSK

UK£67.5b

LSE:AZN

UK£204.5b

AIM:ANCR

UK£161.8m

Price History & Performance

Recent News & Updates

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Recent updates

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022)

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

New minor risk - Profit margin trend

First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022)

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings released: EPS: €7.20 (vs €7.64 in FY 2021)

Full year 2022 earnings released: EPS: €7.20 (vs €7.82 in FY 2021)

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Upcoming dividend of €1.20 per share

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Investor sentiment deteriorated over the past week

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

First half 2021 earnings released: EPS €3.66 (vs €2.65 in 1H 2020)

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)